|
Balance Sheet Cash Flow Statement 4001 Miranda Ave. Palo Alto, CA 94304 CA Tel. 650-812-8700 Fax 650-424-0832 |
Type: Public
On the web:
http://www.affymax.com
Employees:
147
Employee growth: (2.6%)
Affymax is designing peptides to give red blood cells a pep talk. The biotechnology firm is researching and developing possible drugs based upon these biological process regulators. Its leading drug candidate, Hematide, is an erythropoietin (EPO) mimetic, designed to stimulate red blood cell production, like EPO itself. Hematide is being investigated as a possible treatment for anemia caused by chronic renal failure and chemotherapy. Affymax believes Hematide will be cheaper and longer lasting than the EPO stimulants currently used on dialysis patients.
Key numbers for fiscal year ending December, 2008:
Sales: $82.9M
One year growth: 86.9%
Net income: ($86.5)M
Officers:
President, CEO, and Director: Arlene M. Morris
EVP Corporate Development and CFO: Paul B. Cleveland
SVP Technical Operations: Robert F. (Bob) Venteicher
Competitors:
Amgen
Centocor Ortho Biotech
Roche
